Easing concerns, FibroGen, AstraZeneca secure FDA date for their anemia drug in broad chronic kidney disease population

Easing concerns, FibroGen, AstraZeneca secure FDA date for their anemia drug in broad chronic kidney disease population

Source: 
Endpoints
snippet: 

Armed with a new chief following the unexpected passing of longtime CEO Thomas Neff last year, FibroGen is off to the races with its controversial AstraZeneca-partnered anemia drug. The FDA has accepted the company’s application to market the oral therapy — which is positioned to replace the standard of care — in patients with chronic kidney disease regardless of dialysis status.